Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Ventures Raises $230M for First Fund

NEW YORK (GenomeWeb) – Illumina Ventures has raised $230 million for its first fund, which focuses on supporting firms involved in genomics and precision medicine.

Illumina launched the independent, early-stage venture capital firm in 2016 with an investment of $100 million. Since launching, it has raised an additional $130 million from a mix of corporate, institutional, sovereign, and individual investors.

The investment will "allow us to expand our team and support a greater number of entrepreneurs," Nicholas Naclerio, founding partner of Illumina Ventures, said in a statement.

Thus far, the firm has invested in seven companies: Biota Technology, DNA Script, Encoded Genomics, Genome Medical, Kallyope, SerImmune, and Twist Bioscience.

"The rapid advances in genomics are creating tremendous entrepreneurial opportunities across industries from novel therapeutics, diagnostics, and research tools to food security and synthetic biology," Francis deSouza, president and CEO of Illumina, said in a statement.

The Scan

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.

DNA Biobank Developed for French Kidney Donors, Recipients

The KiT-GENIE biobank described in the European Journal of Human Genetics contains DNA samples, genotyping profiles, immune patterns, and clinical features for thousands of kidney donors or transplant recipients in Nantes, France.

Cardiometabolic Disease May Have Distinct Associations With Microbial Metabolites in Blood, Gut

By analyzing gut microbes in combination with related metabolites in feces and blood, researchers in Nature Communications found distinct cardiometabolic disease relationships at each site.

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.